3431 related articles for article (PubMed ID: 20818862)
1. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
[TBL] [Abstract][Full Text] [Related]
2. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
3. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
[TBL] [Abstract][Full Text] [Related]
4. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
[TBL] [Abstract][Full Text] [Related]
5. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
Plosker GL
Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
[TBL] [Abstract][Full Text] [Related]
7. Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.
George DJ; Nabhan C; DeVries T; Whitmore JB; Gomella LG
Cancer Immunol Res; 2015 Sep; 3(9):1063-9. PubMed ID: 25943532
[TBL] [Abstract][Full Text] [Related]
8. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Small EJ; Schellhammer PF; Higano CS; Redfern CH; Nemunaitis JJ; Valone FH; Verjee SS; Jones LA; Hershberg RM
J Clin Oncol; 2006 Jul; 24(19):3089-94. PubMed ID: 16809734
[TBL] [Abstract][Full Text] [Related]
10. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
12. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND
Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
14. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
15. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Huber ML; Haynes L; Parker C; Iversen P
J Natl Cancer Inst; 2012 Feb; 104(4):273-9. PubMed ID: 22232132
[TBL] [Abstract][Full Text] [Related]
16. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.
Hall SJ; Klotz L; Pantuck AJ; George DJ; Whitmore JB; Frohlich MW; Sims RB
J Urol; 2011 Sep; 186(3):877-81. PubMed ID: 21788048
[TBL] [Abstract][Full Text] [Related]
17. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Wei XX; Perry J; Chang E; Zhang L; Hiatt RA; Ryan CJ; Small EJ; Fong L
Clin Genitourin Cancer; 2018 Jun; 16(3):184-190.e2. PubMed ID: 29352713
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
19. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
20. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Sheikh NA; Petrylak D; Kantoff PW; Dela Rosa C; Stewart FP; Kuan LY; Whitmore JB; Trager JB; Poehlein CH; Frohlich MW; Urdal DL
Cancer Immunol Immunother; 2013 Jan; 62(1):137-47. PubMed ID: 22865266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
